Patricia Coutinho de Souza1,2, Krithika Balasubramanian1, Charity Njoku1, Natalyia Smith1, David L Gillespie3, Andrea Schwager4, Osama Abdullah5, Jerry W Ritchey2, Kar-Ming Fung6, Debra Saunders1, Randy L Jensen3,7, Rheal A Towner1,2,6. 1. Advanced Magnetic Resonance Center, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA. 2. Department of Veterinary Pathobiology, College of Veterinary Medicine, Oklahoma State University, Stillwater, Oklahoma, USA. 3. Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA. 4. Interdepartmental Program in Neuroscience, University of Utah, Salt Lake City, Utah, USA. 5. Department of Bioengineering, University of Utah, Salt Lake City, Utah, USA. 6. Department of Pathology, Oklahoma University Health Science Center, Oklahoma City, Oklahoma, USA. 7. Departments of Neurosurgery, Radiation Oncology, Oncological Sciences, Clinical Neurosciences Center, University of Utah, Salt Lake City, Utah, USA.
Abstract
BACKGROUND: Glioblastoma is a malignant World Health Organization (WHO) grade IV glioma with a poor prognosis in humans. New therapeutics are desperately required. The nitrone OKN-007 (2,4-disulfophenyl-PBN) has demonstrated effective anti-glioma properties in several rodent models and is currently being used as a clinical investigational drug for recurrent gliomas. We assessed the regional effects of OKN-007 in the tumor necrotic core and non-necrotic tumor parenchyma. METHODS: An F98 rat glioma model was evaluated using proton magnetic resonance spectroscopy ((1) H-MRS), diffusion-weighted imaging (DWI), morphological T2-weighted imaging (T2W) at 7 Tesla (30 cm-bore MRI), as well as immunohistochemistry and microarray assessments, at maximum tumor volumes (15-23 days following cell implantation in untreated (UT) tumors, and 18-35 days in OKN-007-treated tumors). RESULTS: (1) H-MRS data indicates that Lip0.9/Cho, Lip0.9/Cr, Lip1.3/Cho, and Lip1.3/Cr ratios are significantly decreased (all P < 0.05) in the OKN-007-treated group compared with UT F98 gliomas. The Cho/Cr ratio is also significantly decreased in the OKN-007-treated group compared with UT gliomas. In addition, the OKN-007-treated group demonstrates significantly lower ADC values in the necrotic tumor core and the nonnecrotic tumor parenchyma (both P < 0.05) compared with the UT group. There was also an increase in apoptosis following OKN-007 treatment (P < 0.01) compared with UT. CONCLUSION: OKN-007 reduces both necrosis and tumor cell proliferation, as well as seems to mediate multiple effects in different tumor regions (tumor necrotic core and nonnecrotic tumor parenchyma) in F98 gliomas, indicating the efficacy of OKN-007 as an anti-cancer agent and its potential clinical use.
BACKGROUND:Glioblastoma is a malignant World Health Organization (WHO) grade IV glioma with a poor prognosis in humans. New therapeutics are desperately required. The nitroneOKN-007 (2,4-disulfophenyl-PBN) has demonstrated effective anti-glioma properties in several rodent models and is currently being used as a clinical investigational drug for recurrent gliomas. We assessed the regional effects of OKN-007 in the tumor necrotic core and non-necrotic tumor parenchyma. METHODS: An F98 ratglioma model was evaluated using proton magnetic resonance spectroscopy ((1) H-MRS), diffusion-weighted imaging (DWI), morphological T2-weighted imaging (T2W) at 7 Tesla (30 cm-bore MRI), as well as immunohistochemistry and microarray assessments, at maximum tumor volumes (15-23 days following cell implantation in untreated (UT) tumors, and 18-35 days in OKN-007-treated tumors). RESULTS: (1) H-MRS data indicates that Lip0.9/Cho, Lip0.9/Cr, Lip1.3/Cho, and Lip1.3/Cr ratios are significantly decreased (all P < 0.05) in the OKN-007-treated group compared with UT F98 gliomas. The Cho/Cr ratio is also significantly decreased in the OKN-007-treated group compared with UT gliomas. In addition, the OKN-007-treated group demonstrates significantly lower ADC values in the necrotic tumor core and the nonnecrotic tumor parenchyma (both P < 0.05) compared with the UT group. There was also an increase in apoptosis following OKN-007 treatment (P < 0.01) compared with UT. CONCLUSION:OKN-007 reduces both necrosis and tumor cell proliferation, as well as seems to mediate multiple effects in different tumor regions (tumor necrotic core and nonnecrotic tumor parenchyma) in F98 gliomas, indicating the efficacy of OKN-007 as an anti-cancer agent and its potential clinical use.
Authors: A Pierallini; M Bonamini; P Pantano; F Palmeggiani; M Raguso; M F Osti; G Anaveri; L Bozzao Journal: Neuroradiology Date: 1998-03 Impact factor: 2.804
Authors: R K Gupta; T F Cloughesy; U Sinha; J Garakian; J Lazareff; G Rubino; L Rubino; D P Becker; H V Vinters; J R Alger Journal: J Neurooncol Date: 2000-12 Impact factor: 4.130
Authors: Clifford J Belden; Pablo A Valdes; Cong Ran; David A Pastel; Brent T Harris; Camilo E Fadul; Mark A Israel; Keith Paulsen; David W Roberts Journal: Radiographics Date: 2011-10 Impact factor: 5.333
Authors: Inas S Khayal; Forrest W Crawford; Suja Saraswathy; Kathleen R Lamborn; Susan M Chang; Soonmee Cha; Tracy R McKnight; Sarah J Nelson Journal: J Magn Reson Imaging Date: 2008-04 Impact factor: 4.813
Authors: Frank B Furnari; Tim Fenton; Robert M Bachoo; Akitake Mukasa; Jayne M Stommel; Alexander Stegh; William C Hahn; Keith L Ligon; David N Louis; Cameron Brennan; Lynda Chin; Ronald A DePinho; Webster K Cavenee Journal: Genes Dev Date: 2007-11-01 Impact factor: 11.361
Authors: Rheal A Towner; Nataliya Smith; Debra Saunders; Megan Lerner; Beverley Greenwood-Van Meerveld; Robert E Hurst Journal: Am J Nucl Med Mol Imaging Date: 2020-02-25
Authors: Johannes Kasper; Nicole Hilbert; Tim Wende; Michael Karl Fehrenbach; Florian Wilhelmy; Katja Jähne; Clara Frydrychowicz; Gordian Hamerla; Jürgen Meixensberger; Felix Arlt Journal: Curr Oncol Date: 2021-04-07 Impact factor: 3.677